Since breast cancer patients are faced with the challenge of endocrine resistance, so understanding the ERα signaling activity, including its expression and stability regulation are critical for the development of new anti-estrogen therapies and the defeating of tamoxifen resistance. Here, ESR1 is linked to breast carcinoma.